Insider Buying: Tenax Therapeutics Inc. (TENX) Director Buys 29,882 Shares of Stock
Tenax Therapeutics Inc. (NASDAQ:TENX) Director Gerald T. Proehl bought 29,882 shares of the stock in a transaction that occurred on Wednesday, November 23rd. The stock was bought at an average price of $1.67 per share, with a total value of $49,902.94. Following the completion of the purchase, the director now directly owns 15,433 shares in the company, valued at $25,773.11. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Tenax Therapeutics Inc. (NASDAQ:TENX) traded up 6.21% during mid-day trading on Tuesday, reaching $1.88. 146,941 shares of the company were exchanged. The firm’s market capitalization is $52.86 million. Tenax Therapeutics Inc. has a 1-year low of $1.21 and a 1-year high of $3.40. The stock has a 50-day moving average of $1.68 and a 200 day moving average of $2.29.
Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Thursday, November 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. Equities research analysts forecast that Tenax Therapeutics Inc. will post ($0.65) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Insider Buying: Tenax Therapeutics Inc. (TENX) Director Buys 29,882 Shares of Stock” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/29/insider-buying-tenax-therapeutics-inc-tenx-director-buys-29882-shares-of-stock.html.
About Tenax Therapeutics
Tenax Therapeutics Inc, formerly Oxygen Biotherapeutics, Inc, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company’s principal business is to acquire, or discover, develop, and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and commercial opportunity.
Receive News & Stock Ratings for Tenax Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics Inc. and related stocks with our FREE daily email newsletter.